Ampicillin Trihydrate

Urinary Tract Infections, Endocarditis, Whooping Cough + 17 more
Treatment
19 FDA approvals
20 Active Studies for Ampicillin Trihydrate

What is Ampicillin Trihydrate

AmpicillinThe Generic name of this drug
Treatment SummaryAmpicillin is a type of oral antibiotic derived from penicillin. It works against a wide range of bacterial infections.
Ampicillinis the brand name
Ampicillin Trihydrate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ampicillin
Ampicillin
1971
270

Approved as Treatment by the FDA

Ampicillin, also called Ampicillin, is approved by the FDA for 19 uses such as Recurrent Upper and Lower Respiratory Tract Infections (RTIs) and Infection caused by eikenella corrodens .
Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
Infection caused by eikenella corrodens
disease caused by Salmonella typhi
bacterial skin infections
Urinary Tract Infection (UTI)
Used to treat Bacterial Infections in combination with Sulbactam
Pertussis
Gastrointestinal Tract Infections
Bacterial Infections
Used to treat Bacterial Infections in combination with Sulbactam
perinatal group B streptococcus
Salmonella
Shigella
Listeria infection
Disease
Bacterial Infections
Urinary Tract Infections
Respiratory Tract Infections
Communicable Diseases
Listeriosis
Whooping Cough

Effectiveness

How Ampicillin Trihydrate Affects PatientsAmpicillin is an antibiotic used to treat bacterial infections that are usually caused by certain types of bacteria. It is part of the group of antibiotics called penicillin, which can fight both gram-positive and gram-negative bacteria. Ampicillin works by preventing bacteria from building cell walls, which is done by binding to special proteins in the bacteria. It is also resistant to many beta-lactamases, which are enzymes that can destroy certain types of antibiotics.
How Ampicillin Trihydrate works in the bodyAmpicillin works by attaching to certain proteins found in bacterial cell walls. This prevents the bacteria from finishing the process of building its cell wall, which ultimately causes the bacteria to break apart and die. It is also believed that Ampicillin may interfere with a compound that stops certain enzymes from breaking down the cell wall.

When to interrupt dosage

The measure of Ampicillin Trihydrate relies upon the determined sickness, including Salmonella, Urinary Tract Infection and perinatal group B streptococcus. The dosage varies as per the mode of delivery (e.g. Injection, powder, for solution - Intramuscular; Intravenous or Injection, powder, for solution) noted in the following table.
Condition
Dosage
Administration
Disease
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Urinary Tract Infections
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Endocarditis
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Shigella
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Respiratory Tract Infections
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Gastrointestinal Tract Infections
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Bacterial Infections
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Bacterial Infections
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Urinary Tract Infections
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Whooping Cough
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Communicable Diseases
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
perinatal group B streptococcus
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Salmonella
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Meningitis, Bacterial
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Septicemia
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Listeriosis
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Urinary Tract Infection (UTI)
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Cesarean Section
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Hysterectomy, Vaginal
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet
Infection
, 1000.0 mg/mL, 2000.0 mg/mL, 1000.0 mg, 250.0 mg/mL, 1.0 mg/mg, 2.0 mg/mg, 2000.0 mg, 10000.0 mg, 125.0 mg, 250.0 mg, 500.0 mg, 100.0 mg/mL, 200.0 mg/mL, 5.0 mg/mg, 500.0 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 125.0 mg/mL, 2.5 mg/mg
, Injection, powder, for solution, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for suspension, Injection, powder, for suspension - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, for solution, Oral, Liquid - Oral, Suspension - Oral, Suspension, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule; Tablet, Liquid - Intramuscular; Intravenous, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Capsule; Tablet - Oral, Tablet

Warnings

Ampicillin Trihydrate has one contraindication, so it should not be ingested for the conditions presented in the following table.Ampicillin Trihydrate Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Ampicillin may interact with Pulse Frequency
There are 20 known major drug interactions with Ampicillin Trihydrate.
Common Ampicillin Trihydrate Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ampicillin.
Abacavir
Minor
Ampicillin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Ampicillin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Ampicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Ampicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Ampicillin Trihydrate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ampicillin Trihydrate?

67 active studies are currently being conducted to investigate the potential of Ampicillin Trihydrate in combating Urinary Tract Infection, Communicable Diseases, and Endocarditis.
Condition
Clinical Trials
Trial Phases
Infection
6 Actively Recruiting
Not Applicable, Phase 1
Meningitis, Bacterial
0 Actively Recruiting
Endocarditis
1 Actively Recruiting
Not Applicable
Shigella
2 Actively Recruiting
Phase 2, Phase 1
Bacterial Infections
0 Actively Recruiting
Cesarean Section
0 Actively Recruiting
Septicemia
1 Actively Recruiting
Not Applicable
Urinary Tract Infections
0 Actively Recruiting
Whooping Cough
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Communicable Diseases
0 Actively Recruiting
Listeriosis
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Disease
0 Actively Recruiting
Gastrointestinal Tract Infections
0 Actively Recruiting
Hysterectomy, Vaginal
1 Actively Recruiting
Phase 4
Respiratory Tract Infections
0 Actively Recruiting
Bacterial Infections
0 Actively Recruiting
Salmonella
0 Actively Recruiting
perinatal group B streptococcus
0 Actively Recruiting

Patient Q&A Section about ampicillin trihydrate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is amoxicillin trihydrate used to treat?

"It is used to treat bacterial infections, such as chest infections (including pneumonia) and dental abscesses. It can also be used together with other antibiotics and medicines to treat stomach ulcers. It's often prescribed for children, to treat ear infections and chest infections. Eradacil can also be used to treat other conditions as determined by your doctor."

Answered by AI

What is the meaning of ampicillin trihydrate?

"Ampicillin Trihydrate prevents bacteria from making new cell walls, which eventually leads to the death of the bacteria. This is achieved by binding to proteins that are essential for cell wall synthesis."

Answered by AI

What is ampicillin trihydrate used for?

"It will not work for viral infections (such as common cold, flu).

Ampicillin is used to treat a wide variety of bacterial infections. It is a penicillin-type antibiotic that works by stopping the growth of bacteria. This antibiotic only treats bacterial infections and will not work for viral infections such as the common cold or flu."

Answered by AI

Is ampicillin a strong antibiotic?

"Ampicillin can be an effective antibiotic against a variety of bacteria but is not as commonly prescribed as it used to be because resistance can occur when it is used alone."

Answered by AI

Clinical Trials for Ampicillin Trihydrate

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX
Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.
Waitlist Available
Has No Placebo
Baylor College of MedicineLarissa Grigoryan, MD, PhD
Image of University of North Carolina Urogynecology and Reconstructive Pelvic Surgery at REX in Raleigh, United States.

Bupivacaine-Epinephrine for Postoperative Pain

18+
Female
Raleigh, NC
The goal of the study to see if giving a numbing medicine around the cervix (called a paracervical block) during vaginal hysterectomy with prolapse repair helps people feel less pain and need fewer strong pain medicines afterward. The main question it aims to answer is: • Does receiving a paracervical block at the time of vaginal hysterectomy with prolapse repair reduce postoperative opioid use? Researchers will compare opioid use in participants who receive the an injected numbing medicine (bupivacaine with lidocaine) to those that receive a saltwater liquid placebo. Participants will: * Receive either an injection of the numbing medicine (bupivacaine with lidocaine) or saltwater liquid placebo after they are asleep but before any other parts of the surgery are done * Record and report pain medications used for 7 days after surgery * Report pain scores before discharge from the post anesthesia recovery area on day of surgery as well as 1 and 7 days after surgery * Complete a surgical recovery questionnaire during 6 week postoperative visit * Complete a one page multiple-choice test on pelvic organ prolapse
Phase 4
Recruiting
University of North Carolina Urogynecology and Reconstructive Pelvic Surgery at REXBertie Geng, MD
Have you considered Ampicillin Trihydrate clinical trials? We made a collection of clinical trials featuring Ampicillin Trihydrate, we think they might fit your search criteria.Go to Trials
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Image of Center for Immunization Research in Baltimore, United States.

ShigETEC Vaccine for Dysentery

18 - 50
All Sexes
Baltimore, MD
The purpose of this study is to evaluate the efficacy of the oral, live, attenuated ShigETEC vaccine against challenge with S. flexneri 2457T. In Stage 1 of this study, ShigETEC vaccine or placebo will be administered orally to healthy participants at a dose of 5x10\^10 CFU. This dose was tested in a Phase 1 trial and found to be safe when given 4 times with an interval of 3 days between each dose. The efficacy of ShigETEC vaccination will be evaluated in Stage 2 of this study, when participants will be challenged with S. flexneri 2457T. The study population will be healthy adult participants in the age of 18-50 years (inclusive), which are clearly defined in the study protocol.
Phase 2
Recruiting
Center for Immunization ResearchEveliqure Biotechnologies GmbH
Have you considered Ampicillin Trihydrate clinical trials? We made a collection of clinical trials featuring Ampicillin Trihydrate, we think they might fit your search criteria.Go to Trials
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.
Recruiting
Has No Placebo
Atlantic Health
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Image of Boston Medical Center in Boston, United States.

Recovery Management Checkups for Opioid Use Disorder

18 - 65
All Sexes
Boston, MA
This project is a pilot study of an adapted intervention of an existing Opioid Use Disorder (OUD) treatment retention intervention called Recovery Management Checkups (RMC). This intervention has been adapted to better fit the experiences and unique issues of those that have been hospitalized with serious injection related infections (SIRI) based on the findings from a prior qualitative study from the principal investigator. This project plans to test the adapted intervention within a smaller group of participants to assess feasibility, acceptability, and calculate early findings of intervention efficacy. Hospitalizations for SIRIs are a unique entry point for patients to start their recovery journey with medications for OUD (MOUD), but many people do not remain on long-term treatment, despite evidence that indicates MOUDs reduce death and re-hospitalization after SIRIs. The study objectives are to: * Assess the implementation feasibility of the adapted RMC model for patients with SIRI and OUD. * Establish preliminary estimates of intervention efficacy. * Make further adaptions to the intervention that will reduce both known and unknown barriers to care and increase effectiveness in future larger scale trials. Findings from this pilot study will result in further intervention refinement to better fit the target population, and serve as the basis for a larger randomized control trial that will have aims focused on more in-depth analysis of the efficacy of this program
Recruiting
Has No Placebo
Boston Medical CenterSimeon Kimmel, MD
Image of BayCare Health System in Clearwater, United States.

Machine Learning Monitoring for Clinical Deterioration

18+
All Sexes
Clearwater, FL
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which patients are at increased risk for clinical deterioration. The algorithm specifically predicts imminent death or the need for intensive care unit (ICU) transfer. Within the eCART interface, clinical teams are then directed toward standardized guidance to determine next steps in care for elevated-risk patients. The investigators hypothesize that implementing such a tool will be associated with a decrease in ventilator utilization, length of stay, and mortality for high-risk hospitalized adults.
Waitlist Available
Has No Placebo
BayCare Health System (+2 Sites)Dana P Edelson, MD, MSAgileMD, Inc.
Have you considered Ampicillin Trihydrate clinical trials? We made a collection of clinical trials featuring Ampicillin Trihydrate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security